Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Inside the AI-Healthcare Boom: Breakthroughs in Diagnostics and Personalized Treatment
AI in healthcare is booming, with Mayo Clinic and Elon Musk's Grok AI leading the charge. Major tech companies like Nvidia, Google, and Microsoft showcased healthcare AI tools at the HLTH conference. Avant Technologies and Ainnova Tech formed a joint venture to advance early disease detection using AI, targeting a $67.4 billion market by 2027. Other companies like Recursion Pharmaceuticals, Exscientia, Absci Corporation, and Twist Bioscience are also making strides in AI-driven healthcare innovations.
Insilico Plans Pivotal Trial for AI-Based IPF Candidate
Insilico Medicine plans to advance ISM001-055 into a pivotal study after positive Phase IIa trial results showing efficacy against idiopathic pulmonary fibrosis (IPF). ISM001-055 improved forced vital capacity (FVC) and was safe and well-tolerated. Insilico aims to initiate a global Phase IIb study by the second half of 2025, with Carol Satler, MD, PhD, appointed to oversee the program. The drug targets Traf2- and NCK- interacting kinase (TNIK) and was developed using generative AI.
OpenAI partners with Sanofi, Formation Bio on AI-driven trial recruitment
The article discusses the importance of enabling JavaScript for optimal app performance.
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
Novavax received FDA approval to resume clinical trials for its Covid-19 and influenza combination vaccine (CIC) and standalone influenza vaccines after a month-long hold. The Phase III trial will evaluate the CIC vaccine's efficacy in adults aged 65 and older, comparing its immune response to standard flu and Covid-19 vaccines. Novavax aims to commence enrolment by the end of 2024 with preliminary results by mid-2025.
Related Clinical Trials:
Formation Bio Collaborates with OpenAI and Sanofi to Introduce Muse
Formation Bio, OpenAI, and Sanofi introduce Muse, an AI tool to accelerate drug development by optimizing patient recruitment for clinical trials. Muse analyzes scientific literature and real-world evidence to create comprehensive research and faster recruitment strategies, potentially reshaping healthcare. Sanofi plans to deploy Muse in Phase 3 MS studies, enhancing inclusiveness in trials. Muse includes an LLM agent for regulatory compliance and prioritizes AI safety and data privacy.
Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study
FDA lifts clinical hold on Novavax's COVID-19/influenza combo vaccine after addressing a serious adverse event initially reported as motor neuropathy, now identified as amyotrophic lateral sclerosis. Novavax plans to resume phase 3 trials with its Matrix-M adjuvant, enhancing immune response. The company recently secured FDA EUA for its JN.1-adapted COVID-19 vaccine and a $1.2bn licensing deal with Sanofi for co-commercialization.
Formation Bio collaborates with Sanofi and OpenAI to Introduce Muse, a first of its kind AI
Formation Bio, OpenAI, and Sanofi introduce Muse, an AI tool to optimize patient recruitment for clinical trials, aiming to reduce timelines from months to minutes. Muse analyzes scientific literature and real-world evidence to create tailored recruitment strategies and materials, enhancing inclusiveness in trials. Sanofi plans to deploy Muse in Phase 3 MS studies, leveraging its expertise in innovative treatments.
AI Regulation Sparks Debate at Scope Europe Conference: Industry Leaders Weigh In
At SCOPE Europe, panelists discussed the EU's AI Act's impact on life sciences, fearing stringent regulations could stifle innovation and deter startups. Regional disparities in AI regulation were highlighted, with predictions that companies may pivot to regions with more favorable environments. While some niches like early drug discovery may remain unaffected, smaller enterprises should prepare for increased compliance complexity.
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma
NK cell therapy, a promising cancer treatment, sees robust R&D with 140+ companies developing 160+ therapies. Key players include Amgen, Innate Pharma, Nektar Therapeutics, and others. Promising therapies like Bemarituzumab, Monalizumab, and NKTR-225 are in various clinical phases. Recent milestones include Immunitybio's CAR-NK cell therapy for NHL, Nkarta's NKX019 for AAV, and KGen Biotech's SNK01 advancing to Phase II.
Biopharma Layoffs Roundup
Biopharma layoffs continue into 4Q 2024, affecting companies like Thermo Fisher, Charles River, Pfizer, Evonik, Johnson & Johnson, Bayer, Bristol Myers Squibb, AGC Biologics, and others. These layoffs are part of restructuring initiatives, site closures, and focus shifts in strategic core growth areas.
© Copyright 2024. All Rights Reserved by MedPath